Clinical Trial Update: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study investigating famitinib in combination with HS-10296 for EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Famitinib (Famitinib)
• HS-10296 (HS-10296)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: EGFR-mutant Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN